Home › Allergy › Washington
Allergy clinical trials in Washington, DC
4 studies for Allergy are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia
RecruitingObservational study
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Registry of Asthma Characterization and Recruitment 3 (RACR3)
RecruitingObservational studyHealthy volunteers welcome
- Children's National Medical Center: Inner City Asthma Consortium (ICAC) Clinical Research Site, Washington D.C.
A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up
RecruitingObservational study
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
RecruitingPhase 4
- Children's National Hospital, Washington D.C.
About Allergy
An allergy is a reaction by your immune system. Substances that cause reactions include pollen and food. Find the full list of allergies and symptoms.
More about Allergy on MedlinePlus
Allergy trials in other cities
- Boston, MA6 studies
- New York City, NY6 studies
- Nashville, TN5 studies
- Mountain View, CA4 studies
- Ann Arbor, MI4 studies
- Baltimore, MD3 studies
- Cincinnati, OH3 studies
- Durham, NC3 studies
- Chicago, IL3 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease28 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.